Sorafenib Tosylate Improves Survival in Kidney Cancer

Sorafenib tosylate (Nexavar, Bayer), a new anti-cancer medication for adults with advanced renal cell carcinoma, has been approved. In the U.S., kidney cancer accounts for approximately 3% of all adult cancers.

In two studies, patients who were treated with sorafenib had more time before tumor progression or death. In the larger study, most patients had received interleukin-2 or interferon. The median time to tumor progression or death was 167 days for sorafenib patients and 84 days for controls.